Citations
2 publicationsPublications from researchers using this productDescription
α-NETA is a non-competitive inhibitor of choline acetyltransferase (ChAT; IC50=9μM). α-NETA inhibits ALDH1A1 (IC50=0.04μM) and antagonizes the activity of chemokine-like receptor 1 (CMKLR1), cholinesterase (ChE; IC50=84μM), and acetylcholinesterase (AChE; IC50=300μM). α-NETA can be used in research related to cancer and diabetic nephropathy[1-4].
In vitro, α-NETA (5μM) pretreated human gastric cancer AGS cells for 16-24 hours. α-NETA inhibited Chemerin-induced cell migration and invasion and suppressed cell morphological transformation[5]. α-NETA (3μM) treated chemerin-overexpressing human trophoblast cells (HTR8/SVneo) for 24-48 hours. α-NETA induced cell membrane rupture, cytoplasmic leakage, and activated the GSDMD/caspase-4-mediated pyroptosis pathway by increasing the expression of caspase-4 and GSDMD and the secretion of IL-18[6].
In vivo, α-NETA (30mg/kg; once daily) was administered by gavage to high-fat diet-induced obese C57BL/6 mice for 4 weeks. α-NETA reduced body weight in the mice[7]. α-NETA (10mg/kg; three times per week) was administered via intraperitoneal injection to nude mice bearing UOK101 cell xenograft tumors and SCID mice bearing human ccRCC PDX (UTSW-XP296) models (subcutaneous and orthotopic implantation) for 70 days. α-NETA significantly inhibited tumor growth and reduced lipid deposition within the tumors, while no significant changes in animal health status were observed[8].
References:
[1] Sastry BV, Jaiswal N, Janson V, et al. Relationships between chemical structure and inhibition of choline acetyltransferase by 2-(alpha-naphthoyl)ethyltrimethylammonium and related compounds. Pharmacol Res Commun. 1988 Sep;20(9):751-71.
[2] Graham KL, Zhang JV, Lewén S, et al. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. PLoS One. 2014 Dec 1;9(12):e112925.
[3] Qiao L, Wu X, Zhang J, et al. α-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway. FASEB J. 2019 Nov;33(11):12760-12767.
[4] Aleksandrov AA, Polyakova NV, Vinogradova EP, et al. The TAAR5 agonist α-NETA causes dyskinesia in mice. Neurosci Lett. 2019 Jun 21;704:208-211.
[5] Kumar JD, Aolymat I, Tiszlavicz L, et al. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget. 2019 Jan 4;10(2):98-112.
[6] Tan L, Chen Z, Sun F, et al. Placental trophoblast-specific overexpression of chemerin induces preeclampsia-like symptoms. Clin Sci (Lond). 2022 Feb 25;136(4):257-272.
[7] Zheng C, Zheng Y, Chen X, et al. α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression. BMC Endocr Disord. 2023 Jan 10;23(1):9.
[8] Wang D, Mahmud I, Thakur VS, et al. GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma. Cancer Res. 2024 Jul 2;84(13):2141-2154.
Protocol
| Cell experiment [1]: | |
Cell lines | HTR8/SVneo cells (immortalized human trophoblast cells) |
Preparation Method | HTR8/SVneo cells were maintained in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO₂. Cells were infected with LV-hChemerin-GFP lentivirus to overexpress chemerin, selected with puromycin, and subsequently exposed to either 1% DMSO (vehicle control) or 3μM α-NETA dissolved in DMSO. |
Reaction Conditions | 3μM; 24-48h |
Applications | α-NETA prevented the inhibitory effects of chemerin overexpression on cell migration, invasion, and tube formation in co-culture with human umbilical vein endothelial cells (HUVECs). |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice (male, 8-10 weeks old) |
Preparation Method | Mice were fed a high-fat diet (HFD, 40 kcal% fat, 2% fructose) for 12 weeks to induce obesity. Then, mice in the α-NETA group received daily treatments of α-NETA (30mg/kg) via gavage for 4 weeks. Mice in the α-NETA+PD group received daily treatment of α-NETA plus PD98059 (0.3mg/kg via tail vein injection). At the end of intervention, mice were sacrificed for analysis of body weight, liver histology, ileal CMKLR1 mRNA, and serum parameters. |
Dosage form | 30mg/kg; daily gavage; for 4 weeks |
Applications | α-NETA reduced body weight gain in HFD-induced obese mice. Combined with PD98059, α-NETA further reduced body weight and alleviated hepatic steatosis. α-NETA down-regulated CMKLR1 mRNA expression in ileum. No impact on ileal ZO-1 or pERK protein expression, and no significant changes in serum endotoxin levels. |
References: | |
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for α-NETA
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
